The majority of individuals with Lynch syndrome exhibit malignancies defined by DNA mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-high), which demonstrate significant responses to immunotherapy utilizing anti-PD1/PDL1 checkpoint inhibitors [3, 4]. This evidence concerns the gene PDCD1 and Lynch syndrome.